Hemanext is a privately held medical technology company based in Lexington, MA that is dedicated to improving the quality, safety, efficacy, and cost of transfusion therapy. The company's research and development efforts center on the study of hypoxically stored red blood cells (RBCs). The company's aim is to significantly improve the quality of stored RBCs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/07/22 | $18,000,000 | Series B |
Dr. Ismail Kola | undisclosed |
